Chad M. Kormos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chad M. Kormos has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Nicholas E. Leadbeater
Department of Chemistry, University of Connecticut, 55 North Eagleville Road, Storrs, CT 06269-3060, USA
12 shared publications - Frank Ivy Carroll
Research Triangle Institute , P.O. Box 12194, Research Triangle Park , North Carolina 27709 , United States
9 shared publications Hernán A. Navarro
Research Triangle Institute , P.O. Box 12194, Research Triangle Park , North Carolina 27709-2194 , United States
9 shared publicationsScott P. Runyon
Research Triangle Institute , P.O. Box 12194, Research Triangle Park , North Carolina 27709-2194 , United States
9 shared publicationsJames B. Thomas
Research Triangle Institute , P.O. Box 12194, Research Triangle Park , North Carolina 27709-2194 , United States
8 shared publicationsS. Wayne Mascarella
Research Triangle Institute , P.O. Box 12194, Research Triangle Park, North Carolina 27709-2194, United States
6 shared publications
Latest Publications
- Open Access
- 26 July 2023
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 8 (31) , 28185-28195
Isolation of Hemiketal and Hydroxy Ketone Tautomers of Synthetic Intermediates Each Affording 18-Hydroxycortisol-1,6,7-d3
During the synthesis of deuterated 18-hydroxycortisol,two of thesynthetic intermediates have been found to exist in tautomeric formsas the acyclic 18-hydroxy 20-ketone and the cyclic 18,20-hemiketalcorresponding to the previously identified less polar (L) and morepolar (M) forms of C-18 hydroxylated steroids, respectively. Specifically, p-chloranil oxidation of 18-hydroxycortisol-17,21-acetonideafforded two isomers of the 6,7-dehydro analogue; separate catalyticreduction of each isomer under deuterium gave a single isomer of acetonide-protected18-hydroxycortisol-1,6,7-d ( 3 ) for each, with the more polar isomer giving a more polar productand the less polar isomer giving a less polar product. The more polarproduct (corresponding to M) was characterized as 18,20-hemiketal;18-hydroxycortisol-17,21-acetonide-18,20-hemiketal-1,6,7-d ( 3 ): in the deuterochloroform solution,it was found to slowly convert to a substance consistent with thehydroxy ketone structure with features resembling those of the isolatedless polar isomer (corresponding to L). Deacetonidization of eachgave 18-hydroxycortisol as a single product, which was characterizedas the 18,20-hemiketal. The issues associated with the existence of18-hydroxysteroids as hydroxy ketones and hemiketals, both in solutionand as isolable solids, are discussed.
- 26 July 2023
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 8 (31) , 28185-28195
Open AccessIsolation of Hemiketal and Hydroxy Ketone Tautomers of Synthetic Intermediates Each Affording 18-Hydroxycortisol-1,6,7-d3
During the synthesis of deuterated 18-hydroxycortisol,two of thesynthetic intermediates have been found to exist in tautomeric formsas the acyclic 18-hydroxy 20-ketone and the cyclic 18,20-hemiketalcorresponding to the previously identified less polar (L) and morepolar (M) forms of C-18 hydroxylated steroids, respectively. Specifically, p-chloranil oxidation of 18-hydroxycortisol-17,21-acetonideafforded two isomers of the 6,7-dehydro analogue; separate catalyticreduction of each isomer under deuterium gave a single isomer of acetonide-protected18-hydroxycortisol-1,6,7-d ( 3 ) for each, with the more polar isomer giving a more polar productand the less polar isomer giving a less polar product. The more polarproduct (corresponding to M) was characterized as 18,20-hemiketal;18-hydroxycortisol-17,21-acetonide-18,20-hemiketal-1,6,7-d ( 3 ): in the deuterochloroform solution,it was found to slowly convert to a substance consistent with thehydroxy ketone structure with features resembling those of the isolatedless polar isomer (corresponding to L). Deacetonidization of eachgave 18-hydroxycortisol as a single product, which was characterizedas the 18,20-hemiketal. The issues associated with the existence of18-hydroxysteroids as hydroxy ketones and hemiketals, both in solutionand as isolable solids, are discussed.
- 24 March 2022
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 13 (7) , 1082-1095
Identification of a Potent Human Trace Amine-Associated Receptor 1 Antagonist
Human trace amine-associated receptor subtype 1 (hTAAR1) is a G protein-coupled receptor that has therapeutic potential for multiple diseases, including schizophrenia, drug addiction, and Parkinson’s disease (PD). Although several potent agonists have been identified and have shown positive results in various clinical trials for schizophrenia, the discovery of potent hTAAR1 antagonists remains elusive. Herein, we report the results of structure–activity relationship studies that have led to the discovery of a potent hTAAR1 antagonist (RTI-7470-44, 34). RTI-7470-44 exhibited an IC50 of 8.4 nM in an in vitro cAMP functional assay, a Ki of 0.3 nM in a radioligand binding assay, and showed species selectivity for hTAAR1 over the rat and mouse orthologues. RTI-7470-44 displayed good blood–brain barrier permeability, moderate metabolic stability, and a favorable preliminary off-target profile. Finally, RTI-7470-44 increased the spontaneous firing rate of mouse VTA dopaminergic neurons and blocked the effects of the known TAAR1 agonist RO5166017. Collectively, this work provides a promising hTAAR1 antagonist probe that can be used to study TAAR1 pharmacology and the potential therapeutic role in hypodopaminergic diseases such as PD.
- 24 March 2022
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 13 (7) , 1082-1095
Identification of a Potent Human Trace Amine-Associated Receptor 1 Antagonist
Human trace amine-associated receptor subtype 1 (hTAAR1) is a G protein-coupled receptor that has therapeutic potential for multiple diseases, including schizophrenia, drug addiction, and Parkinson’s disease (PD). Although several potent agonists have been identified and have shown positive results in various clinical trials for schizophrenia, the discovery of potent hTAAR1 antagonists remains elusive. Herein, we report the results of structure–activity relationship studies that have led to the discovery of a potent hTAAR1 antagonist (RTI-7470-44, 34). RTI-7470-44 exhibited an IC50 of 8.4 nM in an in vitro cAMP functional assay, a Ki of 0.3 nM in a radioligand binding assay, and showed species selectivity for hTAAR1 over the rat and mouse orthologues. RTI-7470-44 displayed good blood–brain barrier permeability, moderate metabolic stability, and a favorable preliminary off-target profile. Finally, RTI-7470-44 increased the spontaneous firing rate of mouse VTA dopaminergic neurons and blocked the effects of the known TAAR1 agonist RO5166017. Collectively, this work provides a promising hTAAR1 antagonist probe that can be used to study TAAR1 pharmacology and the potential therapeutic role in hypodopaminergic diseases such as PD.
- Open Access
- 16 April 2020
- Published by Wiley in The FASEB Journal
- Vol. 34 (S1) , 1
Design of first in class bitopic ligands targeting the sodium binding pocket in opioid receptors
Opioid agonists have been used in the field of pain management for centuries, but are considered a major public health concern, especially in the US. One of the biggest challenges consists in understanding the ability to target specifically the different subtypes of opioid receptors and to trigger a specific functional response correlating with an in vivo analgesic response devoid of side‐effects. These opioid receptors are part of the GPCRs family, which is known to have common features across different subfamilies. One important feature of these receptors is the presence of allosteric binding pockets, which is progressively gaining momentum as a novel target for current therapeutic strategies. We hypothesized that targeting an allosteric site could potentially allow for receptor functional selectivity, helping to reduce the overall side effects profile. One site, in particular, known as the Na + binding pocket, is known to play a key role in GPCR function and is thought to be the center of the functional mechanism, with several bias switches characterized in the pocket residues (Katritch et al ., Trends Biochem Sci . 2014). Here we report structure‐based rational drug design of bitopic ligands targeting the Na + pocket of mu (MOR) and kappa opioid receptors (KOR). Our designed bitopics show high affinity, subtype selectivity, G‐protein bias and analgesic actions in mice. Mutations in Na + binding pocket diminished functional potency validating allosteric site targeting. Together, results suggest the possibility of achieving subtype selectivity and identification of an additional subpocket in both MOR and KOR to reduce βarrestin‐2 recruitment by targeting an allosteric pocket in the opioid receptors. The highly conserved constitution of the Na + binding pocket opens the opportunity for rational discovery of new GPCR modulators with desired functional, and potentially therapeutic profile for opioids as well as other class A GPCRs. Support or Funding Information: We gratefully acknowledge the financial support from Faculty Research Incentive Fund, NIDA, NIAAA and US department of defense. We also would like to thank the Philippe Foundation for their financial support.
- 16 April 2020
- Published by Wiley in The FASEB Journal
- Vol. 34 (S1) , 1
Open AccessDesign of first in class bitopic ligands targeting the sodium binding pocket in opioid receptors
Opioid agonists have been used in the field of pain management for centuries, but are considered a major public health concern, especially in the US. One of the biggest challenges consists in understanding the ability to target specifically the different subtypes of opioid receptors and to trigger a specific functional response correlating with an in vivo analgesic response devoid of side‐effects. These opioid receptors are part of the GPCRs family, which is known to have common features across different subfamilies. One important feature of these receptors is the presence of allosteric binding pockets, which is progressively gaining momentum as a novel target for current therapeutic strategies. We hypothesized that targeting an allosteric site could potentially allow for receptor functional selectivity, helping to reduce the overall side effects profile. One site, in particular, known as the Na + binding pocket, is known to play a key role in GPCR function and is thought to be the center of the functional mechanism, with several bias switches characterized in the pocket residues (Katritch et al ., Trends Biochem Sci . 2014). Here we report structure‐based rational drug design of bitopic ligands targeting the Na + pocket of mu (MOR) and kappa opioid receptors (KOR). Our designed bitopics show high affinity, subtype selectivity, G‐protein bias and analgesic actions in mice. Mutations in Na + binding pocket diminished functional potency validating allosteric site targeting. Together, results suggest the possibility of achieving subtype selectivity and identification of an additional subpocket in both MOR and KOR to reduce βarrestin‐2 recruitment by targeting an allosteric pocket in the opioid receptors. The highly conserved constitution of the Na + binding pocket opens the opportunity for rational discovery of new GPCR modulators with desired functional, and potentially therapeutic profile for opioids as well as other class A GPCRs. Support or Funding Information: We gratefully acknowledge the financial support from Faculty Research Incentive Fund, NIDA, NIAAA and US department of defense. We also would like to thank the Philippe Foundation for their financial support.
- 17 August 2018
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 61 (17) , 7525-7545
Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3R)-7-Hydroxy-N-[(1S)-2-methyl-1-(piperidin-1-ylmethyl)propyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (PDTic)
Past studies have shown that it has been difficult to discover and develop potent and selective κ opioid receptor antagonists, particularly compounds having potential for clinical development. In this study, we present a structure–activity relationship (SAR) study of a recently discovered new class of tetrahydroisoquinoline κ opioid receptor antagonists which led to (3R)-7-hydroxy-N-{(1S)-2-methyl-1-[(−4-methylpiperidine-1-yl)methyl]propyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (12) (4-Me-PDTic). Compound 12 had a Ke = 0.37 nM in a [35S]GTPγS binding assay and was 645- and >8100-fold selective for the κ relative to the μ and δ opioid receptors, respectively. Calculated log BB and CNS (central nervous system) multiparameter optimization (MPO) and low molecular weight values all predict that 12 will penetrate the brain, and pharmacokinetic studies in rats show that 12 does indeed penetrate the brain.
- 17 August 2018
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 61 (17) , 7525-7545
Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3R)-7-Hydroxy-N-[(1S)-2-methyl-1-(piperidin-1-ylmethyl)propyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (PDTic)
Past studies have shown that it has been difficult to discover and develop potent and selective κ opioid receptor antagonists, particularly compounds having potential for clinical development. In this study, we present a structure–activity relationship (SAR) study of a recently discovered new class of tetrahydroisoquinoline κ opioid receptor antagonists which led to (3R)-7-hydroxy-N-{(1S)-2-methyl-1-[(−4-methylpiperidine-1-yl)methyl]propyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (12) (4-Me-PDTic). Compound 12 had a Ke = 0.37 nM in a [35S]GTPγS binding assay and was 645- and >8100-fold selective for the κ relative to the μ and δ opioid receptors, respectively. Calculated log BB and CNS (central nervous system) multiparameter optimization (MPO) and low molecular weight values all predict that 12 will penetrate the brain, and pharmacokinetic studies in rats show that 12 does indeed penetrate the brain.
- 22 July 2018
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 61 (17) , 7546-7559
Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3R)-N-[1R)-1-(Cyclohexylmethyl)-2-methylpropyl]-7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (CDTic)
Animal pharmacological studies suggest that potent and selective κ opioid receptor antagonists have potential as pharmacotherapies targeting depression, anxiety, and substance abuse (opiates, alcohol, nicotine, cocaine). We recently reported lead compound 1 as a new class of κ opioid receptor antagonists with only one basic amine group. Analogues were synthesized and evaluated for their in vitro opioid receptor antagonist properties using a [35S]GTPγS binding assay. All analogues were pure opioid receptor antagonists with no agonist activity. Compounds 1, 8, 9, 13, and 14 (Ke values 0.058–0.64 nM) are highly potent and highly selective for the κ relative to the μ and δ opioid receptors. Favorable calculated physiochemical properties were confirmed in rat PK studies, demonstrating brain penetration for selected compounds 1, 9, and 13. High κ opioid receptor potency and selectivity and highly favorable calculated physiochemical and PK properties for brain penetration suggest these compounds should be considered for further development.
- 22 July 2018
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 61 (17) , 7546-7559
Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3R)-N-[1R)-1-(Cyclohexylmethyl)-2-methylpropyl]-7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (CDTic)
Animal pharmacological studies suggest that potent and selective κ opioid receptor antagonists have potential as pharmacotherapies targeting depression, anxiety, and substance abuse (opiates, alcohol, nicotine, cocaine). We recently reported lead compound 1 as a new class of κ opioid receptor antagonists with only one basic amine group. Analogues were synthesized and evaluated for their in vitro opioid receptor antagonist properties using a [35S]GTPγS binding assay. All analogues were pure opioid receptor antagonists with no agonist activity. Compounds 1, 8, 9, 13, and 14 (Ke values 0.058–0.64 nM) are highly potent and highly selective for the κ relative to the μ and δ opioid receptors. Favorable calculated physiochemical properties were confirmed in rat PK studies, demonstrating brain penetration for selected compounds 1, 9, and 13. High κ opioid receptor potency and selectivity and highly favorable calculated physiochemical and PK properties for brain penetration suggest these compounds should be considered for further development.
- 1 June 2017
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 8 (7) , 742-745
Simple Tetrahydroisoquinolines Are Potent and Selective Kappa Opioid Receptor Antagonists
Potent and selective κ opioid receptor antagonists have been derived from the N-substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class of pure opioid receptor antagonists. In order to determine if the 3-hydroxyphenyl and/or the piperidine amino groups are required for obtaining the pure opioid antagonists, (3R)-7-hydroxy-N-[(1S)-2-methyl-1-(piperidine-1-ylmethyl)propyl]-1,2,3,4-tetrahydroiosquinoline-3-carboxamide (1), which does not have a 4-(3-hydroxyphenyl) group, and (3R)-N-(1R)-1-(cyclohexylmethyl)-2-methylpropyl]-7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (2), which does not have a 4-hydroxylphenyl or a piperidine amino group, were synthesized and evaluated for their [35S]GTPγS binding properties at the μ, δ, and κ opioid receptors. Surprisingly compound 1 remained a pure opioid antagonist with a Ke = 6.80 nM at the κ opioid receptor and is 21- and 441-fold selective for the κ receptor relative to the μ and δ opioid receptors, respectively. Even more unexpected and novel is the finding that 2 has a Ke = 0.14 nM at κ and is 1730- and 4570-fold selective for κ relative to the μ and δ opioid receptors, respectively.
- 1 June 2017
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 8 (7) , 742-745
Simple Tetrahydroisoquinolines Are Potent and Selective Kappa Opioid Receptor Antagonists
Potent and selective κ opioid receptor antagonists have been derived from the N-substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class of pure opioid receptor antagonists. In order to determine if the 3-hydroxyphenyl and/or the piperidine amino groups are required for obtaining the pure opioid antagonists, (3R)-7-hydroxy-N-[(1S)-2-methyl-1-(piperidine-1-ylmethyl)propyl]-1,2,3,4-tetrahydroiosquinoline-3-carboxamide (1), which does not have a 4-(3-hydroxyphenyl) group, and (3R)-N-(1R)-1-(cyclohexylmethyl)-2-methylpropyl]-7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (2), which does not have a 4-hydroxylphenyl or a piperidine amino group, were synthesized and evaluated for their [35S]GTPγS binding properties at the μ, δ, and κ opioid receptors. Surprisingly compound 1 remained a pure opioid antagonist with a Ke = 6.80 nM at the κ opioid receptor and is 21- and 441-fold selective for the κ receptor relative to the μ and δ opioid receptors, respectively. Even more unexpected and novel is the finding that 2 has a Ke = 0.14 nM at κ and is 1730- and 4570-fold selective for κ relative to the μ and δ opioid receptors, respectively.
- 2 August 2016
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 81 (21) , 10383-10391
Design, Synthesis, and Biological Evaluation of Structurally Rigid Analogues of 4-(3-Hydroxyphenyl)piperidine Opioid Receptor Antagonists
In order to gain additional information concerning the active conformation of the N-substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine (1) class of opioid receptor antagonists, procedures were developed for the synthesis of structurally rigid N-substituted-6-(3-hydroxyphenyl)3-azabicyclo[3.1.0]hexane and 3-methyl-4-(3-hydroxyphenyl)-4-azabicyclo[4.1.0]heptanes. Evaluation of the conformationally constrained series in a [35S]GTPγS assay showed that structural rigid compounds having the 3-hydroxyphenyl group locked in the piperidine equatorial orientation had potencies equal to or better than similar compounds having more flexible structures similar to 1. The studies of the rigid compounds also suggested that the 3-methyl group present in compound 1 type antagonists may not be necessary for their pure opioid antagonist properties.
- 2 August 2016
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 81 (21) , 10383-10391
Design, Synthesis, and Biological Evaluation of Structurally Rigid Analogues of 4-(3-Hydroxyphenyl)piperidine Opioid Receptor Antagonists
In order to gain additional information concerning the active conformation of the N-substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine (1) class of opioid receptor antagonists, procedures were developed for the synthesis of structurally rigid N-substituted-6-(3-hydroxyphenyl)3-azabicyclo[3.1.0]hexane and 3-methyl-4-(3-hydroxyphenyl)-4-azabicyclo[4.1.0]heptanes. Evaluation of the conformationally constrained series in a [35S]GTPγS assay showed that structural rigid compounds having the 3-hydroxyphenyl group locked in the piperidine equatorial orientation had potencies equal to or better than similar compounds having more flexible structures similar to 1. The studies of the rigid compounds also suggested that the 3-methyl group present in compound 1 type antagonists may not be necessary for their pure opioid antagonist properties.
- 1 August 2016
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 24 (16) , 3842-3848
Design, synthesis, and pharmacological evaluation of JDTic analogs to examine the significance of replacement of the 3-hydroxyphenyl group with pyridine or thiophene bioisosteres
- 1 August 2016
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 24 (16) , 3842-3848
Design, synthesis, and pharmacological evaluation of JDTic analogs to examine the significance of replacement of the 3-hydroxyphenyl group with pyridine or thiophene bioisosteres
- 1 October 2015
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 23 (19) , 6379-6388
Design, synthesis, and pharmacological evaluation of JDTic analogs to examine the significance of the 3- and 4-methyl substituents
- 1 October 2015
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 23 (19) , 6379-6388
Design, synthesis, and pharmacological evaluation of JDTic analogs to examine the significance of the 3- and 4-methyl substituents